U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H14F3NO
Molecular Weight 269.2623
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-998425

SMILES

O[C@@H]1CCCC[C@@H]1C2=CC=C(C#N)C(=C2)C(F)(F)F

InChI

InChIKey=MENRRRXHFQYXDW-DGCLKSJQSA-N
InChI=1S/C14H14F3NO/c15-14(16,17)12-7-9(5-6-10(12)8-18)11-3-1-2-4-13(11)19/h5-7,11,13,19H,1-4H2/t11-,13-/m1/s1

HIDE SMILES / InChI
PF-998425 is a selective non-steroidal androgen receptor antagonist. It is rapidly metabolized systemically, and demonstrated efficacy for treatment of androgenic alopecia in preclinical model.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
37.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Male C3H/HeN mice were shaved under isoflurane anesthesia on the lower back using an electric shaver. Only mice in the telogen phase (pink skin) were used in studies. Twenty microliters of test articles at various concentrations in propylene glycol/ethanol (30:70, v/v) or the vehicle control was topically applied to the shaved lower back of the mice to cover an area of approximately 1 cm2 (20uL/cm2). Ten mice were used in each experimental group. The treatment regimen was twice daily (BID) application for 4 weeks, 5 days/week from Monday to Friday. Local irritation was recorded before each application and hair growth scores were recorded every other day.
Route of Administration: Topical
The competitive radio-ligand binding analysis was performed on human AR extracts from transfected baculovirus/Sf9 cells in the presence or absence of differing concentrations of test agent and a fixed concentration of 3H-dihydrotestosterone (3H-DHT) as tracer. Progressively decreasing concentrations of compounds are incubated in the presence of human AR extracts, hydroxylapatite and, 1 nM 3H-DHT for 1 h at 4 °C. Subsequently, the binding reaction mixtures are washed three times to completely remove excess unbound 3H-DHT. AR bound 3H-DHT levels are determined in the presence of compounds and compared to levels of receptor specific binding when no competitor is present. Compound binding affinity to the human AR is expressed as the concentration of compound at which 50% of the maximum specific binding is inhibited (IC50). PF-998425 binds to AR and displaces radioligand with an IC50 of 37 nM.
Name Type Language
PF-998425
Common Name English
BENZONITRILE, 4-((1R,2R)-2-HYDROXYCYCLOHEXYL)-2-(TRIFLUOROMETHYL)-
Systematic Name English
4-((1R,2R)-2-HYDROXYCYCLOHEXYL)-2(TRIFLUOROMETHYL)BENZONITRILE
Systematic Name English
(R,R)-(-)-2-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)CYCLOHEXANOL
Systematic Name English
Code System Code Type Description
CAS
1076225-27-8
Created by admin on Sat Dec 16 08:12:08 GMT 2023 , Edited by admin on Sat Dec 16 08:12:08 GMT 2023
PRIMARY
PUBCHEM
25093231
Created by admin on Sat Dec 16 08:12:08 GMT 2023 , Edited by admin on Sat Dec 16 08:12:08 GMT 2023
PRIMARY
FDA UNII
OY0E00K11M
Created by admin on Sat Dec 16 08:12:08 GMT 2023 , Edited by admin on Sat Dec 16 08:12:08 GMT 2023
PRIMARY